Retinal cell map could advance precise therapies for blinding diseases
May 14, 2022
A discovery by investigators at the National Eye Institute sheds light on tissue targeted by age-related macular degeneration and other diseases.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
AMD
Safety data for at-home subcutaneous injection option for treatment of wet AMD, DME
May 25, 2022
Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous injection option being developed for wet AMD and DME. The anti-VEGF candidate will enter a Phase 2 study later this year.
VLRC Eye Van making 50th anniversary tour
May 14, 2022
The Eye Van, operated by Vision Loss Rehabilitation Canada, is a mobile medical clinic that delivers eye care in northern Ontario communities where ophthalmology services aren't readily available.
MacuLogix reaches milestone with 1 million dark adaptation tests
May 12, 2022
As more and more practices embrace dark adaptation testing, AdaptDx technology has become a staple in primary eye care.
Cell therapy trial shows promising results for patients with advanced dry AMD
May 10, 2022
The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).
Unraveling genes, mutations in inherited retinal diseases
May 05, 2022
Variable TULP1 missense mutations in inherited retinal diseases.
Axitinib Intravitreal Implant for wet AMD delivered high drug levels to retinal tissue
May 01, 2022
The intravitreal implant (OTX-TKI) is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.
Retrospective study of AMD remote monitoring shows improved outcomes for patients
April 27, 2022
According to the ALOFT study, patients demonstrate improved long-term vision in real-world setting after wet AMD conversion compared to current standard of care.
Outlook Therapeutics submits Biologics License Application to FDA for ONS-5010 as a treatment for Wet AMD
March 31, 2022
If the BLA is approved, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.
Graybug Vision announces pipeline expansion
March 30, 2022
The company is planning a Phase 2 trial with an optimized formulation in wet AMD that is expected to start in fourth quarter of 2022.